The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in Schizophrenia
Schizophrenia, Clozapine, Hypersalivation
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, clozapine, hypersalivation, Suo Quan Wan, Wu Lin San
Eligibility Criteria
Inclusion Criteria:
1.20 year and older. All genders. 2.Psychiatry doctor diagnosed schizophrenia or schizoaffective disorder will be recruited for participation in this study.
3.Using clozapine as an antipsychotic drug and has a side-effect of hypersalivation.
4.Testee agree and sign informed consent forms to do this experiment.
Exclusion Criteria:
- Use clozapine as an antipsychotic drug not over 8 weeks.
- Testee have other diseases could influence saliva secretion, such as Parkinson's disease.
- Pregnant, prepare to pregnant within half a year or in the lactation period.
Add or alter following medicines within 2 weeks:
4.1 Central acting 2-adrenergic receptor agonist 4.2 anticholinergic/antimuscarinic drugs 4.3 b-adrenoreceptor blockers, diphenhydramine, botulinum toxin injection
- Testee's lever function test (AST/ALT) is higher than 3 (4 weeks medication).
- Testee's kidney function test (Cr) is higher than 2.5mg/dl (4 weeks medication).
- Testee have participate other medicine trial within one month.
Sites / Locations
- Taichung Veterans General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo Comparator
ChinesMed